STING1 and ovarian cancer: We used siRNA to transiently deplete 80% of STING (Figure 2B) in the BRCA1-negative UWB1.289 ovarian cancer cell line and subjected the depleted cells and controls to the labeling regimen depicted in Figure 2A.